Non-small cell lung cancer with BRAF V600E mutation

Non-small cell lung cancer with a BRAF V600E mutation is a distinct molecular subtype of primary thoracic epithelial malignancy, most frequently manifesting as lung adenocarcinoma Pathophysiologically, this alteration causes constitutive, monomeric activation of the MAPK/ERK downstream signaling cascade independently of upstream RAS stimulation, promoting unregulated tumor cell proliferation, survival, and disease progression

Non-small cell lung cancer with a BRAF V600E mutation is a distinct molecular subtype of primary thoracic epithelial malignancy, most frequently manifesting as lung adenocarcinoma Clinically, identification of this biomarker defines an actionable oncogenic driver population sensitive to selective BRAF and MEK inhibition

This condition primarily affects adults and is characterized by a specific valine-to-glutamic acid substitution at codon 600 of the BRAF kinase Pathophysiologically, this alteration causes constitutive, monomeric activation of the MAPK/ERK downstream signaling cascade independently of upstream RAS stimulation, promoting unregulated tumor cell proliferation, survival, and disease progression Clinically, identification of this biomarker defines an actionable oncogenic driver population sensitive t...